XML 40 R31.htm IDEA: XBRL DOCUMENT
v3.21.2

Schedule of Fair Value of Aggregate Merger Consideration (Details) - USD ($) $ / shares in Units, $ in Thousands |  | 1 Months Ended
--- | --- | ---
Apr. 15, 2021 | Jan. 31, 2020
Insight Merger Agreements [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Cash consideration | [1] |  | $ 7,000
Shares of Oncocyte common stock issued on the Merger Date | [2] |  | 1,915,692,000
Closing price per share of Oncocyte common stock on the Merger Date |  |  | $ 2.61
Market value of Oncocyte common stock issued |  |  | $ 5,000
Contingent Consideration | [3] |  | 11,130
Total fair value of consideration transferred on the Merger Date |  |  | $ 23,130
Chronix Biomedica lInc [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Cash consideration |  | $ 3,960 |
Shares of Oncocyte common stock issued on the Merger Date |  | 647,911 |
Closing price per share of Oncocyte common stock on the Merger Date |  | $ 5.09 |
Market value of Oncocyte common stock issued |  | $ 3,298 |
Contingent Consideration |  | 42,295 |
Total fair value of consideration transferred on the Merger Date |  | 50,103 |
Settlement of Acquirer/Acquiree Activity Pre-Combination, net |  | $ 550 |
[1] | The cash consideration paid on the Insight Merger Date was $6.4 million, which was net of a $0.6 million cash holdback discussed above, recorded as a holdback liability since Oncocyte retained the cash. In accordance with ASC 805, amounts held back for general representations and warranties of the sellers are included as part of the total consideration transferred.
[2] | The 229,885 Stock Holdback shares were placed in an escrow account and considered to be issued and outstanding Oncocyte common stock. In accordance with ASC 805, amounts held back for general representations and warranties of the sellers, including escrowed shares of common stock, are included as part of the total consideration transferred.
[3] | In accordance with ASC 805, Contingent Consideration, at fair value, is part of the total considered transferred on the Insight Merger Date, as further discussed below.

X
- Definition Closing price per share of Oncocyte common stock on the Merger Date. + References No definition available. + Details
Name: | OCX_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfPerShare
Namespace Prefix: | OCX_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Settlement of Acquirer/Acquiree Activity Pre-Combination, net. + References No definition available. + Details
Name: | OCX_BusinessCombinationAcquireeActivityPreCombinationNet
Namespace Prefix: | OCX_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Consideration. + References No definition available. + Details
Name: | OCX_BusinessCombinationContingentConsiderationArrangementsBasisForAmounts
Namespace Prefix: | OCX_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total fair value of consideration transferred on the Merger Date. + References No definition available. + Details
Name: | OCX_FairValueOfConsiderationTransferredOnMergerDate
Namespace Prefix: | OCX_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business. + References No definition available. + Details
Name: | us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=OCX_InsightMergerAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=OCX_ChronixBiomedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |